Xevudy Helps GSK Ride Out Depressed Shingrix Sales
But COVID-19 Profits Will Drop In 2022
GlaxoSmithKline is preparing for the long-awaited spin-out of its consumer division later this year but needs to see Shingrix bounce back from its pandemic blues to help the company reignite growth.
You may also be interested in...
Coronavirus Update: Canadian Evusheld Supply Deal, Nuvaxovid EU Shipments
The US places certain limits on the use of GSK's Xevudy, while Canada signs a supply deal for another antibody therapy, AstraZeneca's Evusheld. Meanwhile, Novavax starts EU shipments of its vaccine and the UK funds ConserV's pan-coronavirus vaccine.
Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.
Vertex’s Sickle Cell Treatment Gets December Decision Date, On Track To Be First CRISPR Therapy
Vertex now looks likely to gain US approval for the first ever CRISPR gene edited therapy by the end of the year, but could face immediate competition from Bluebird Bio.